Selective μ opioid receptor antagonist.
Sold with the permission of the University of Minnesota
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||20mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 490.99. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.04 mL||10.18 mL||20.37 mL|
|5 mM||0.41 mL||2.04 mL||4.07 mL|
|10 mM||0.2 mL||1.02 mL||2.04 mL|
|50 mM||0.04 mL||0.2 mL||0.41 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Jiang et al (1990) μ Antagonist and κ agonist properties of β-funaltrexamine (β-FNA) in vivo: long lasting spinal analgesia in mice. J.Pharmacol.Exp.Ther. 252 1006 PMID: 2156986
Takemorei et al (1981) The irreversible narcotic antagonist and reversible agonist properties of the fumarate methyl ester derivative of naltrexone. Eur.J.Pharmacol. 70 445 PMID: 6263637
If you know of a relevant reference for β-Funaltrexamine hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Irreversible μ-opioid mu-opioid selective antagonists MOP Receptors OP3 β-Funaltrexamine beta-Funaltrexamine hydrochloride β-FNA beta-FNA b-FNA Mu Opioid Receptors
5 Citations for β-Funaltrexamine hydrochloride
Citations are publications that use Tocris products. Selected citations for β-Funaltrexamine hydrochloride include:
Chen et al (2015) Berberine Improves Intestinal Motility and Visceral Pain in the Mouse Models Mimicking Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Symptoms in an Opioid-Receptor Dependent Manner. Neuropsychopharmacology 10 e0145556 PMID: 26700862
Romero-Picó et al (2013) Hypothalamic κ-opioid receptor modulates the orexigenic effect of ghrelin. Circulation 38 1296 PMID: 23348063
Tzeng et al (2011) Myricetin Ameliorates Defective Post-Receptor Insulin Signaling via β-Endorphin Signaling in the Skeletal Muscles of Fructose-Fed Rats. Evid Based Complement Alternat Med 2011 150752 PMID: 21785619
Largent-Milnes et al (2010) Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Br J Pharmacol 161 986 PMID: 20977451
Cecchi et al (2008) Differential responses to morphine-induced analgesia in the tail-flick test. Behav Brain Res 194 146 PMID: 18656501
Do you know of a great paper that uses β-Funaltrexamine hydrochloride from Tocris? If so please let us know.
Literature in this Area
Peptides Involved in Appetite Modulation Scientific Review
Written by Sonia Tucci, Lynsay Kobelis and Tim Kirkham, this review provides a synopsis of the increasing number of peptides that have been implicated in appetite regulation and energy homeostasis; putative roles of the major peptides are outlined and compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.